Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48.0Revenue (TTM) $M7.5Net Margin (%)-245.2Altman Z-Score-19.8
Enterprise Value $M31.1EPS (TTM) $-0.5Operating Margin %-246.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score0.3Pre-tax Margin (%)-245.2Higher ROA y-yY
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio3.4Cash flow > EarningsN
Price/Sales5.65-y EBITDA Growth Rate %--Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-82.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-121.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PSDV

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PSDV is held by these investors:



PSDV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lurker NancyPresident and CEO 2017-06-14Buy56,700$1.76-28.41view
Ross Leonard SVice President, Finance 2016-01-04Sell5,000$4.7-73.19view
Ross Leonard SVice President, Finance 2015-12-22Sell33,950$5.39-76.62view
Ashton PaulPresident & CEO 2015-12-22Sell120,000$5.39-76.62view
Ross Leonard SVice President, Finance 2015-12-01Sell1,050$4.06-68.97view
Ross Leonard SVice President, Finance 2015-08-03Sell5,000$4.05-68.89view
Ashton PaulPresident & CEO 2014-10-01Sell10,000$4.27-70.49view
Ashton PaulPresident & CEO 2014-09-02Sell10,000$4.78-73.64view
Ashton PaulPresident & CEO 2014-08-01Sell10,000$4.37-71.17view
Ashton PaulPresident & CEO 2014-07-01Sell10,000$4.32-70.83view

Press Releases about PSDV :

Quarterly/Annual Reports about PSDV:

    News about PSDV:

    Articles On GuruFocus.com
    pSivida to Present at Rodman & Renshaw Annual Global Investment Conference Sep 11 2017 
    pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 1 Sep 05 2017 
    pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017 Aug 01 2017 
    Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Jul 18 2017 
    Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis Jul 10 2017 
    pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveit Jul 10 2017 
    pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Jun 22 2017 
    pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achiev Jun 13 2017 
    Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences May 08 2017 
    pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th Apr 19 2017 

    More From Other Websites
    No related articles found.

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}